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CASO CLÍNICO
1. Hospital Geral de Santo António - Centro Hospitalar do Porto
(c-ANCA), almost exclusively caused by antibodies
against proteinase 3, and a perinuclear pattern 
(p-ANCA) which can be caused by a variety of antibo-
dies reacting with different neutrophil granule consti-
tuents as myeloperoxidase (MPO), human leucocyte
elastase and lactoferrin1. Etiology of ANCA-associated
vasculitis is largely unknown. There is evidence that
drugs2,3 from different classes, such as antibiotics, anti-
-thyroid, anti-tumor necrosis factor-alfa and psychoac-
tive agents, can cause vasculitis in sporadic cases4,5. Pro-
pylthiouracil (PTU) is one of the most frequent drug
implicated. Despite the high prevalence of PTU-indu-
ced ANCA (estimated from 20-64% in cross sectional
studies) only a subset of patients develop clinical sig-
nificant ANCA-associated vasculitis (AAV)6,7,8,9. The me-
chanisms involved in PTU-induced AAV are far from
being fully understood. The spectrum of manifestations
is wide and ranges from less specific syndromes to sin-
gle organ involvement and life-threatening vasculitis6.
We report a case of PTU-induced AAV with systemic in-
volvement and life threatening manifestations.
cAse report
A 65-year-old portuguese woman was admitted for un-
controlled hyperthyroidism in perspective for thyroid
surgery. Ten years before she had a diagnosis of hy-
perthyroidism and since then she was treated with me -
thi mazole, which was suspended one year before with
evidence of controlled disease. She had a past of smo-
king with chronic bronchitis, hypercholesterolemia,
hypertension, venous insufficiency and a long history
of hypersensitivity to many drug classes, described
mostly as skins lesions. Eight weeks before the admis-
sion she was started on PTU (150mg/day) due to a re-
lapse of hyperthyroidism (TSH<0.008 uIU/mL, 
NR 0,27-4,2uUI/mL, free T3=17.70 ng/dL, NR 2,0-4-
-4pg/mL, and free T4=4.93 ng/L, NR 0,93-1,7ng/dL).
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AbstrAct
The development of antineutrophil cytoplasmatic an-
tibody (ANCA) during therapy with propylthiouracil
(PTU) is not uncommon but occasionally has clinical
significance. Risk factors associated with the develop-
ment of ANCA associated systemic vasculitis when ta-
king PTU have been described. We report and discuss
a case with PTU-induced ANCA vasculitis with severe
systemic manifestations.
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resumo
O desenvolvimento de anticorpos anti-citoplasma de
neutrófilos (ANCA) durante o tratamento com propil-
tiouracilo (PTU) não é raro, no entanto, apenas em al-
guns casos tem significado clínico. Alguns fatores de
risco de desenvolvimento de vasculite sistémica asso-
ciada a ANCA com a toma de PTU têm sido descritos.
Apresentamos e discutimos um caso de vasculite asso-
ciada a ANCA induzida pelo PTU com graves reper-
cussões sistémicas.
Palavras-chave: ANCA; Vasculite sistémica; PTU
IntroductIon
Anti-neutrophil cytoplasmatic antibodies (ANCA) are
significant markers for certain small-vessel vasculitis,
like Wegeners granulomatosis, Churg-Strauss syndro-
me, renal limited vasculitis, anti-glomerular basement
membrane antibody disease or inflammatory bowel di-
seases. Two patterns are recognized: a cytoplasmatic 
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Six weeks later she developed fever and dry cough.
She was admitted in the emergency department whe-
re she presented leucopenia (660/uL, NR 4000-
-11000/uL) with severe neutropenia (20/uL, NR 2000-
-7500/uL), without anemia or thrombocytopenia.
Chest x-ray was clear, urine sediment and blood gas
analyses were normal. Her MASCC risk score for fe-
brile neutropenia was 24. She was diagnosed with
agranulocytosis secondary to PTU and upper respira-
tory tract infection. PTU was suspended, blood cultu-
res were collected and she was sent home in treatment
with ciprofloxacin, prednisolone and propranolol.
Reevaluated three days later she had better neutrophils
count (340/uL, NR 2000-7500/uL) and thyroid func-
tion (TSH=0.01uUI/mL, NR 0,27-4,2uUI/mL, free
T3=6.1pg/mL, NR 2,0-4-4pg/mL and free T4=2.0 
ng/dL, NR 0,93-1,7ng/dL), but she maintained fever
and was proposed for admission as inpatient for clini-
cal surveillance and subsequent thyroid surgery. She
started on lugols solution for surgery preparation but
at 48-72 hours she developed symptoms of sialoade-
nitis and a purpuric rash with papules, nontender or
pruri ginous, mostly in the face, trunk and upper limbs,
with palmar and plantar involvement (Figures 1 and 2).
She then evolved with abdominal pain, in a belt pat-
FIGure 1. Purpuric rash with papules, non tender or 
pruriginous, mostly in the face FIGure 2. Purpuric rash with papules, non tender or 
pruriginous, with palmar and plantar involvement
FIGure 3. Chest radiography with bilateral multiple patchy
opacities
FIGure 4. Toraco-abdomino tomography (without iv 
contrast) with bilateral multifocal consolidation along the 
bronchovascular bundle with mild ground-glass opacity 
and splenic infarctations
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At this point the diagnosis of systemic p-ANCA vas-
culitis was made, with polyglandular, lung, splenic and
skin involvement, probably secondary to PTU. She
went on a short course of high dose metylprednisolo-
ne (1g/day), following of 1mg/kg of prednisolone (two
weeks with subsequent withdraw) and thyroid surge-
ry, with complete vasculitis remission, with ANA and
p-ANCA levels returning negativel six months later.
dIscussIon
The mechanisms of PTU-induced AAV are ill-defined
and are probably multifactorial. PTU may play an im-
munogenic effect on T cells, which stimulates B cells
producing ANCA, and also by binding to MPO, it may
modify the configuration of the neutrophils resulting
with triggered autoimmune response6,10. This probably
explains the p-ANCA pattern with production of anti-
-MPO classically described in these cases. PTU-indu-
ced AAV seem to develop mostly in younger females,
probably because of greater prevalence of thyroid di-
sease in young women6. Long-standing therapy using
PTU might be a risk factor for developing clinically evi-
dent vasculitis and relapse of hyperthyroidism was re-
ported as another risk factor11-13, which occurred in our
patient. The clinical manifestations of PTU-induced
AAV are similar to those of other primary vasculitis.
Kidney is the most common involved organ, featuring
from mild hematuria and proteinuria to rapidly pro-
gressive glomerulonephritis. Cutaneous involvement
is also common and may present as different patterns
tern, accompanied by a rise in pancreatic enzymes, and
a rapidly progressive respiratory distress and global res-
piratory failure associated with hypotension responsi-
ve to volume. At this time she was admitted in ICU de-
partment, with extensive areas of skin necrosis and res-
piratory failure (ratio pO2/FiO2<200). Laboratory va-
lues showed hypoproliferative anemia, elevation of
pancreatic enzymes (amylase=600U/L, NR 0-
-53U/L, and lipase=624U/L, NR 30-190U/L), mild he-
maturia (2 to 5 erythrocytes/field of 400x, NR 0-2
erythrocytes/fiel of 400x) and subnephrotic proteinu-
ria (protein/creatinine 1,0g/mmol, NR < 0,45g/mmol)
without dysmorphic erythrocytes, elevated erytrocyte
sedimentation rate and C-reactive protein. Culture tests
were consistently negative. Immunologic studies sho-
wed hypergammaglobinemia (IgM),complement con-
sumption (C3=76,0mg/dL, NR 81-167mg/dL, and
C4=7,0mg/dL, NR 11-43mg/dL), positive ANA with a
speckled pattern (1/320, NR<1/80) and ANCA (1/640,
NR <1/20) with a perinuclear pattern with elevated
anti-MPO antibodies. Anti-double-stranded DNA, anti-
-Sm, anti-U1 ribonucleic protein, anti-SSA, anti-SSB
and anti-histones) were all negative. Chest radiographs
now showed bilateral multiple patchy opacities (Figu-
re 3) and a chest-abdominal CT scan revealed bilateral
multifocal consolidation along the bronchovascular
bundle with mild ground-glass opacity and splenic in-
farctations (Figures 4 and 5). Histological examination
of skin lesoins biopsy showed leucocytoclastic vascu-
litis (Figure 6) - Direct and indirect immunofluores-
cence were not available.
FIGure 5. Toraco-abdomino tomography (without iv 
contrast) with bilateral multifocal consolidation along the 
bronchovascular bundle with mild ground-glass opacity 
and splenic infarctations
FIGure 6. Skyn biopsy with leukocystoclastic vasculitis (x40)
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of skin changes12,14, while pulmonary manifestations
more commonly occur as alveolar hemorrhage with
some patients presenting interstitial pneumonia and
acute respiratory distress syndrome6. In the presented
case, our patient evolved mostly with skin involvement,
confirmed by histology, and interstitial lung disease,
from which we unfortunately did not get a bronchoal-
veolar lavage. In 1994 Chapell Hill Conference defi-
ned the criteria for AAV, which was updated by Gae et
al6 at 2009 with three more criteria added: clinical fin-
dings related to the suspected drug and resolving with
its discontinuation, serum ANCA positivity and exclu-
sion of other conditions mimicking vasculitis. Syste-
mic lupus erythematosus (SLE) was also considered,
namely drug-induced SLE. This diagnosis was disre-
garded attending to the absence of musculoskeletal
complains, serositis and other characteristic clinical fin-
dings in our patient and the absence of SLE antibodies
other than low titer ANA. By opposite, the patient age,
proeminent lung and skin involvement and serum 
p-ANCA high titer made AAV the most probable dia -
gnosis15,16. Regarding treatment, primary vasculitis pa -
thogenesis is different from PTU-induced AAV, and
treatment should be based on individual assessment. In
PTU-induced AAV an immediate cessation of the drug
after diagnosis will probably be enough for those with
clinically limited disease. For patients with severe and
active organ involvement intensive steroid therapy
(with or without immunosuppressive agents) can im-
prove organ function and prevent progression to seve-
re, irreversible disease6,11. Maintenance therapy may
not be necessary11. The overall outcome of PTU-indu-
ced AAV is much better than primary vasculitis proba-
bly because of cessation of the potential immunogenic
stimulus.
conclusIon
Since many patients treated with PTU have ANCA po-
sitivity but only few develop systemic vasculitis syn-
dromes, early recognition of signs and symptoms rela-
ted to vasculitis is the best way to prevent the worst
consequences6. ANCA screening without clinical ma-
nifestations showed no benefit10.
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